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Objectives
The clinical utility of routine cross sectional imaging of the abdomen and pelvis in the screening 
and surveillance of patients with primary soft-tissue sarcoma of the extremities for metastatic 
disease is controversial, based on its questionable yield paired with concerns regarding the risks 
of radiation exposure, cost, and morbidity resulting from false positive findings.
Methods
Through retrospective review of 140 patients of all ages (mean 53 years; 2 to 88) diagnosed 
with soft-tissue sarcoma of the extremity with a mean follow-up of 33 months (0 to 291), we 
sought to determine the overall incidence of isolated abdominopelvic metastases, their 
temporal relationship to chest involvement, the rate of false positives, and to identify 
disparate rates of metastases based on sarcoma subtype.
Results
A total of four patients (2.9%) exhibited isolated abdominopelvic metastatic disease during 
the surveillance period. In all cases of concomitant chest and abdominopelvic disease, chest 
involvement preceded abominopelvic involvement. There was a significant false positive 
rate requiring invasive workup.
Conclusions
In the setting of a relative paucity of evidence concerning a rare disease process and in 
difference to recently published investigations, we add a clinical cohort not supportive of 
routine cross sectional imaging of the abdomen and pelvis.
Cite this article: Bone Joint Res 2015;4:45–9.
Article focus
 To determine the utility of CT of the
abdomen/pelvis in staging and surveil-
lance of soft-tissue sarcoma of the
extremity
 To identify soft-tissue sarcoma types
more prone to isolated abdominal
metastases
 To identify the rate and effects of false
positive CT
Key messages
 Isolated metastases to the abdomen/
pelvis are rare
 Concomitant chest/abdomen metastases
affect the chest first
 False positive findings lead to invasive
work ups with potential complications 
Strengths and limitations
 Strength: We add a large cohort of a rare
condition to a relative paucity of literature
supporting the standard of care, which
calls for imaging the chest alone, in differ-
ence to a recent publication
 Limitation: potential for significant selec-
tion bias
 Limitation: inadequate sample size to
make conclusions regarding risk of
metastases of specific sarcoma types
Introduction
Soft-tissue sarcoma of the extremity is a rare
entity,1,2 which becomes distantly metastatic
in approximately 20% to 30% of patients,
uncorrected for tumour grade.2-4 Most
patients who develop metastases will do so
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within two to five years of diagnosis, 75% involving the
chest,1,2,5 and with a significant portion presenting
symptomatically.3 The current standard of care for newly
diagnosed extremity soft-tissue sarcoma involves imag-
ing of the chest for staging and surveillance for metastatic
lesions.3,6-9 Most sarcomas have been felt to spread first to
the lungs prior to extra-pulmonary sites, however, spe-
cific sarcoma sub-types have been previously observed to
spread to the abdomen initially.6,10,11 The observation of
isolated abdominal metastatic disease is rare,6,10-12 but
leads to many centres routinely imaging the abdomen/
pelvis as a measure of screening and surveillance. The
utility of this practice has been recently investigated by
King et al,6 and based on a larger than expected rate of
abdominal involvement (both isolated and in conjunc-
tion with pulmonary disease) the authors were led to
consider routine screening and surveillance (CT) of the
abdomen/pelvis in all patients with all types of soft-tissue
sarcoma of the extremity.
Identification of prognostic factors for development of
abdominal disease would benefit clinicians in deter-
mining which patients should undergo screening with
CT, sparing others excessive radiation, cost, and potential
morbidity from false positive findings. However, the cur-
rent available literature does not provide clear direction in
this regard. Given increasing concerns for lifetime radia-
tion exposure,13,14 costs of potentially unnecessary tests,
and the unexpected results of the aforementioned work,
we proposed to study the diagnostic utility of CT imaging
of the abdomen/pelvis for metastatic disease in primary
extremity soft-tissue sarcoma to determine if our experi-
ence was supportive of this practice.
We pose the following questions: What is the incidence
of chest versus abdominopelvic metastatic disease at the
time of diagnosis (screening) or in surveillance of patients
with soft-tissue sarcoma of the extremities? What is the
coincidence and temporal relationship of chest versus
abdominopelvic metastases? Do specific soft-tissue sar-
coma sub-types exhibit disparate rates of metastasis or
show propensity for abdomen/pelvis involvement? What
is the rate and consequence of false positive results when
the modality is routinely employed, and what cost does
this impart on the healthcare system?
Patients and Methods
Following institutional review board approval, by retro-
spective review of the medical record at a single tertiary
care centre with two practicing fellowship-trained
musculoskeletal oncologists, we identified potential
patients by performing a query of the electronic medical
record using ICD-9 codes 171.2 and 171.3 for malignant
neoplasm of the upper extremity and lower extremity,
respectively. A full chart review was performed on all
patients who had undergone CT chest/abdomen/pelvis
(C/A/P) to determine the number of abdomen/pelvis CTs
obtained, the presence of metastases on a given CT scan,
the temporal relationship of chest to abdominopelvic
metastases, and additional work up that was performed
due to a positive CT result. Primary endpoints were pres-
ence of abdominal or pelvic metastasis on staging or sur-
veillance CT C/A/P and sarcoma type. Secondary
endpoints included incidental findings from abdomino-
pelvic imaging, further diagnostic or surgical procedures
performed as a result of said findings, and temporal rela-
tionship of chest to abdominopelvic metastases.
All patients, including children, adults, and inmates
seen clinically between January 2006 and August 2013
were included in the study population, with a mean
follow-up of 32.8 months (0 to 291). Mean patient age
was 53 years (2 to 88). Malignant tumours of all histolog-
ical grades were included. From the initial population of
queried study subjects, 469 patients underwent initial
chart review looking solely at pathology reports for sar-
coma type. Patients with benign lesions, bone lesions,
metastases, and skin malignancies were excluded,
thereby leaving 306 patient charts for review. We chose
not to include primary pelvic lesions in our data set. Of
these 306 patients, we identified 140 patients who had
undergone screening and/or surveillance CT C/A/P. We
included all CT scans for which we had electronic or
paper reports.
A total of 140 patients were included in the study pop-
ulation. Percent positive values were calculated for any
form of metastatic disease, abdominopelvic metastatic
disease, pulmonary metastatic disease, and isolated
abdominopelvic metastatic disease. These data were fur-
ther characterised based on time of study collection
(screening or surveillance), and the percentage of
patients with metastatic disease who had isolated
abdomen/pelvis metastases.
Temporality of the diagnosis of chest and abdomino-
pelvic metastases was then examined and presented as
percentage of patients with both chest and abdomen/
pelvis involvement presenting simultaneously or in the
chest or abdomen/pelvis at disparate time points. Time to
diagnosis of chest and abdominal metastases were calcu-
lated in those who had positive abdominal imaging. Total
rate of metastatic disease of the chest and abdomen/
pelvis at screening and surveillance was then recorded by
tumour tissue type. Finally, percentages of positive CT
scans not representing metastatic disease were tabulated
as the false positive rate. Charts of those patients under-
going further diagnostic work up were identified and
invasive tests and associated complications were
recorded and described.
Results
Of 140 patients, 55 (39%) with primary soft-tissue
sarcoma of the extremity had metastatic disease identi-
fied on either chest or abdominal imaging. In total
51patients’ (36.4%) metastatic disease involved only the
chest, whereas four (2.9%) exhibited isolated abdominal
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metastases, and ten (7.1%) had metastases of both the
chest and abdomen/pelvis. A total of 14 patients (10%)
had abdominal or pelvic metastases identified by abdom-
inal CT scan, one (0.7%) at diagnosis and 13 (9.3%) on
surveillance imaging (Table I).
Isolated abdominal metastatic disease represented
7% of patients with any metastases and 28.6% of the
subset with abdominal metastases. Of ten patients with
metastases to both the chest and abdomen/pelvis, none
developed evidence of disease of the abdomen/pelvis
prior to evidence of chest involvement. Whereas six of
ten (60%) patients developed evidence of metastases to
the chest prior to the abdomen/pelvis, four (40%) were
found to have both pulmonary and abdominopelvic
metastases at the same time. Of those with abdomino-
pelvic metastases, the average time to diagnosis of chest
or abdomen/pelvis metastases was 17 (n = 10) and 19
(n = 14) months, respectively. Those with isolated
abdominal metastases had an average disease-free inter-
val of 12 months (n = 4).
A total of 11 of 21 sarcoma types represented in the
cohort developed extra-pulmonary metastases (Table II).
Relatively prevalent sarcoma types (n > 5) within the
cohort that when metastatic disease had a higher per-
centage (> 20%) of abdominal or pelvic involvement,
were epithelioid sarcoma, leiyomyosarcoma, liposar-
coma, spindle cell sarcoma, and synovial sarcoma. Iso-
lated abdominal metastases were observed in one each of
clear cell sarcoma, pleomorphic sarcoma, myxoid lipo-
sarcoma, and rhabdomyosarcoma. Three of 24 patients
with liposarcoma of any type developed metastases. One
of 14 myxoid liposarcoma developed metastatic disease,
which was isolated to the pelvis, and two of ten patients
with other liposarcoma developed abdominal disease.
Of 19 patients (13.6%) with positive CTs of the abdomen/
pelvis, 14 (73.7%) had metastatic disease. There were six
false-positive results necessitating further diagnostic work,
four of which were invasive with a significant complication
in one of four. Based on the 2013 Medicare fee schedule for
bundled CPT 74177 (CT abdomen/pelvis with contrast), the
cost of a single CT of the abdomen and pelvis is $483.15 A
total of 212 such diagnostic studies were performed in this
cohort of patients, estimating a total cost to the healthcare
system of $102 500, or $25 625 to identify a single patient
with isolated metastases of the abdomen/pelvis.
Discussion
The diagnostic utility of routinely obtaining CTs of the
abdomen/pelvis in the screening and surveillance of
patients with extremity soft-tissue sarcoma for the
development of metastatic disease is in question.6 Approx-
imately one third of patients will develop metastatic dis-
ease, 75% involving the chest,1,2 and therefore most
authors endorse routine imaging of the chest alone, unless
further imaging is indicated clinically.3,7,8,9 The observation
of isolated abdominal metastatic disease is rare,6,12 but has
led to many centres routinely imaging the abdomen/pelvis
as a measure of screening and surveillance. Identification
of prognostic factors for development of abdominal
disease would benefit clinicians in determining which
patients should undergo screening with CT, sparing others
excessive radiation, cost, and potential morbidity from
false positive findings. However, the current available liter-
ature does not provide clear direction.
Table I. Patients with metastatic disease of the abdomen/pelvis
Patient Sarcoma Age (yrs)
Chest mets
staging
A/P mets 
staging
Time to chest mets 
surveillance (mths)
Time to A/P mets 
surveillance (mths) Location
14366 Kaposiform 
hemangioendothelioma
27 No No 50 50 Pelvic lymph 
nodes, 
abdominal
16481 Epithelioid sarcoma 23 No No 8 18 Liver
33917 Epithelioid sarcoma 27 No No 4 5 Iliopsoas
34482 Spindle cell sarcoma 73 No No 8 20 Mesenteric
34981 Clear cell sarcoma of 
tendon sheath
40 No No N/A 18 Inguinal lymph 
nodes 
40729 Spindle cell sarcoma 23 No No 6 6 Bony
43768 Synovial sarcoma 18 No No 97 97 Peritoneal
45974 Leiomyosarcoma 74 Yes No - 4 Liver 
46259 Rhabdomyosarcoma 71 No No N/A 4 Inguinal lymph 
nodes 
59750 Pleomorphic lipo-
sarcoma
56 Yes No - 7 Multiple
61489 Myxoid liposarcoma 64 No No N/A 8 Inguinal lymph 
nodes
80066 Pleomorphic sarcoma 76 No No N/A 6 Liver
88902 Leiomyosarcoma 63 Yes Yes - - Liver
97186 Pleomorphic sarcoma 48 No No 6 9 Inguinal lymph 
nodes, pelvic 
sidewall
A, abdomen; P, pelvis; Mets, metastases
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By retrospectively reviewing our own experience, we
sought to determine if the occurrence of abdominopelvic
metastatic disease in our population with primary soft-
tissue sarcoma of the extremity warranted routine imag-
ing of the abdomen/pelvis.
Our study is retrospective and, thus, prone to the weak-
nesses of this type of investigation. Foremost is the risk of
sampling bias as it could be hypothesised that patients
who developed metastatic disease in any form would be
more likely to undergo imaging of the abdomen/pelvis in
this cohort. As a standardised protocol was not in place
prospectively, the decision to image the abdomen/pelvis
was made clinically by the involved practitioners. This may
add additional selection bias due to the possibility that a
perception of a higher risk of metastatic disease may have
led to a higher likelihood that the abdomen/pelvis would
be imaged. Similarly, observations of temporality are lim-
ited by the relative propensity to image the chest more
commonly than the abdomen, which may also negatively
skew our observed incidence of isolated abdominal meta-
static disease. Finally, our sample size of 140 patients was
not large enough to perform formal differential statistical
analysis based on sarcoma sub-type. Despite these limita-
tions, a relatively large sample of patients with an average
follow-up period of 33 months is presented.
The overall rate of metastases to distant sites of 39%
observed in the current study is comparable with some
prior reports7,10 and slightly higher than others.1,4,6,11 In
total 10% of the current cohort experienced metastatic
disease to the abdomen or pelvis based on either screen-
ing or surveillance imaging, which is comparable with
prior investigations.6 Only one had evidence of abdo-
men/pelvic metastatic disease at diagnosis, whereas there
were 13 positive exams on surveillance imaging, suggest-
ing that surveillance imaging may have a higher diag-
nostic yield than screening when a diagnosis of soft-tissue
sarcoma is known prior to staging. Based solely on these
rates, one may consider routine imaging of the abdomen
and pelvis as warranted.
However, when considering the incidence of isolated
abdomen/pelvis metastases and the temporal relation-
ship of development of chest versus abdomen/pelvis
lesions in patients with both, it is harder to support rou-
tinely imaging the abdomen/pelvis in all patients with
primary soft-tissue sarcoma of the extremity. Only 2.9%
of patients developed isolated abdominal metastases,
which represented 7% of those with metastatic disease of
any type. Of those patients who developed both chest
and abdominal/pelvic metastases in the current popula-
tion, none developed evidence of abdominal disease
prior to its discovery in the chest. King et al6 reported sim-
ilar findings, with 5% isolated abdominal disease and no
cases of abdominal involvement preceding chest involve-
ment when both were present.
Based on the results of previous authors1,4,10,14 and
nationally endorsed guidelines as summarised by King
et al,6 a rational approach may be to image the chest in all
patients with primary soft-tissue sarcoma of the extremity
at diagnosis and during the follow-up period. Additional
imaging of the abdomen/pelvis should be considered for
large tumours of high grade in deep locations or in those
with clinical signs warranting further investigation.1-5,7,11
Table II. Metastatic disease by sarcoma type
Sarcoma type Pts
Total patients 
with Mets
Chest mets 
staging
Chest mets 
surveillance
A/P mets
staging
A/P mets 
surveillance
Pleomorphic sarcoma 25 10 2 7 1
Leiyomyosarcoma 19 10 4 6 1 1
Myxoid Liposarcoma 14 1 1
Pleomorphic sarcoma not otherwise specified 14 7 1 6 1
Epithelioid Sarcoma 12 4 4 2
Synovial Sarcoma 12 4 1 3 1
Liposarcoma, other 10 2 1 1 1
Spindle cell 8 6 5 2
Chondrosarcoma 5 2 2
Extraskeletal osteosarcoma 3 2 2
Fibrosarcoma 3 1 1
Rhabdomyosarcoma 3 1 1
Alveolar soft part 2 2 1 1
Clear cell 2 1 1
MPNST 2 1 1
Angiosarcoma 1
Extraskeletal Ewing 1
Kaposiform hemangioendothelioma 1 1 1 1
Malignant myopericytoma 1
Myxoid sarcoma 1
Post-radiation sarcoma 1 1
Total (%) 140 55 (39) 10 (7) 41 (29) 1 (1) 13 (9)
Pts, patients; Mets, metastases; A, abdominal; P, pelvic; MPNST, malignant peripheral nerve sheath tumour
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This strategy would be improved if sarcoma sub-types
more prone to metastasising to the abdomen/pelvis could
be reliably identified. However, low sample sizes, and dis-
parate observations make this difficult.2,6,12 Similar to pre-
vious work, in this study we identified a higher rate of
abdominopelvic involvement (when metastatic) with epi-
thelioid sarcoma, leiyomyosarcoma, liposarcoma, spindle
cell sarcoma, and synovial sarcoma. However, consistent
with King et al6, only three of 24 liposarcomas were
observed to spread to the abdomen/pelvis in contrast to
the findings of Cheng et al10 and Zananrini and
Sugarbaker12 only one myxoid liposarcoma developed iso-
lated abdominal metastatic disease. Our and other sample
sizes make reliable statistical analysis unreliable and larger
sample sizes collected in a prospective fashion based on a
standardised protocol will be required to make more reli-
able conclusions in this regard.
Finally, when exploring whether or not to employ a
specific diagnostic modality, the potential morbidity
resulting from its use and its cost must be weighed
against its diagnostic yield. No definite conclusions may
be drawn from our dataset. However, relative to results
that would significantly affect treatment (very few), a
large radiation exposure, cost, and high false positive rate
with the potential complications of expensive and inva-
sive testing as a result of non-malignant findings should
not be ignored.
The routine use of CT of the abdomen and pelvis in the
staging and surveillance of all patients with primary soft-
tissue sarcoma of the extremity for metastases is not
necessarily supported by the current study. As the major-
ity of metastastic disease in this cohort involved the chest
either prior to or alongside abdominal/pelvic involve-
ment, routine imaging of the chest should be performed
with the decision to image the abdomen/pelvis being
based on previously described tumour characteristics and
clinical findings (as presented by previous publications
and discussed above). Insufficient data exist to base this
decision on sarcoma subtype. Radiation exposure, cost,
and the consequences of false positives should not be
ignored when deciding whether or not to image the
abdomen/pelvis routinely during staging or surveillance
protocols. Further prospective controlled studies with
large sample size using a standardised clinical protocol
and longer follow-up, are needed.
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